Loading...
Loading...
OXiGENE, Inc.
OXGN, a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced the presentation today of data from a
Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal
choroidal vasculopathy (PCV), which has features similar to age-related
macular degeneration (AMD), a degenerative eye disease.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in